Jon Faiz Kayyem - Nov 19, 2024 Form 4 Insider Report for Inhibrx Biosciences, Inc. (INBX)

Role
Director
Signature
/s/ Kelly Deck, as attorney-in-fact to Jon Faiz Kayyem
Stock symbol
INBX
Transactions as of
Nov 19, 2024
Transactions value $
$1,523,620
Form type
4
Date filed
11/22/2024, 04:03 PM
Previous filing
Jun 24, 2024
Next filing
Dec 6, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction INBX Common Stock Purchase $496K +34.8K +214.42% $14.23 51.1K Nov 19, 2024 By Child A F1, F2
transaction INBX Common Stock Purchase $496K +34.8K +214.42% $14.23 51.1K Nov 19, 2024 By Child B F1, F3
transaction INBX Common Stock Purchase $266K +18.8K +36.7% $14.19 69.8K Nov 20, 2024 By Child A F2, F4
transaction INBX Common Stock Purchase $266K +18.8K +36.7% $14.19 69.8K Nov 20, 2024 By Child B F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares were purchased in multiple transactions at prices ranging from $14.09 to $14.25, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
F2 These securities are directly owned by a custodial account managed by the reporting person for the benefit of the reporting person's minor child, Child A. The reporting person disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein.
F3 These securities are directly owned by a custodial account managed by the reporting person for the benefit of the reporting person's minor child, Child B. The reporting person disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein.
F4 The shares were purchased in multiple transactions at prices ranging from $13.93 to $14.25, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.